The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...
Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback